4 July 2024

Tag: biotechnology

Top 5 stock gainers and losers December 1, 2023: JPWR.H, PM.C, CRD.V

Building on yesterdays report, we will take a quick look at todays top 5 stock gainers and losers up or down double digits on the Canadian stock markets. Here is a summary of the intraday action of assets: Top 5 Gainers Jade Power Trust (JPWR.H) Market Cap ~ $2.67 million Jade Power Trust is a…

1 December 2023
Three biotech stocks you may have missed

Kezar Life Sciences Inc. Between 2020 and 2021, year-over-year (YoY) funding in the biotech market increased by an impressive 39.6%. Currently, some of the biggest trends in this market include personalized medicine, drug research, artificial intelligence, big data, and synthetic biology. In total, the biotech market is expected to increase from USD$852.88 billion in 2020,…

5 July 2022
BetterLife Pharma (BETR.C) products show promise, but how’s their timing?

Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you after proving that it has these benefits during the regulatory dance, you take it to a new market, rebrand it and resell it. Easy. Or you…

30 September 2021
Revive Therapeutics (RVV.C) incredible patent-portfolio explained

Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…

5 July 2021
Bioasis Technologies (BTI.V) and the painful price of private sector science

Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…

24 June 2021
Cybin (CYBN.E) new tryptamine patent improves outcome quality

Cybin (CYBN.E) filed a new provisional patent application for its ongoing drug candidate programs today, according to a press release. The application includes compositions which the company anticipates will improve pharmacokinetic profiles while keeping efficacy measures of the original molecules. The company’s patent also offers new delivery systems to increase onset of Cybin’s psychedelic tryptamine,…

24 May 2021
Mountain Valley MD Holdings (MVMD.C) new patent and preclinicals put cancer in their sights

Mountain Valley MD Holdings (MVMD.C) filed a cancer patent and is moving forward with preclinical trials with third party cancer research organizations (CROs) in triple-negative breast cancer, metastatic melanoma and lung carcinoma, according to a press release. The patent is called Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies, and involves solubilized ivermectin (also…

5 May 2021
Revive Therapeutics (RVV.C) latest spate of Bucillamine research could slow COVID-19 infection rates

Revive Therapeutics (RVV.C) signed a research agreement with the University of California, San Francisco (UCSF) to explore Bucillamine as a potential treatment for severe cases of COVID-19 today, according to a press release. The research will be done by Dr. John Fahy with the intention of testing the efficacy of Bucillamine in pre-clinical models of…

4 May 2021
Core One Labs (COOL.C) takes their artificial psilocybin research to UBC

Core One Labs (COOL.C) subsidiary, Vocan Biotechnologies, and the University of British Columbia (UBC), came to terms on a collaborative research agreement today, according to a press release. The collaboration gives Vocan access to a well-funded, world-class research facility and team to enhance their position in the nascent psychedelic medicine space, especially given the increasing…

27 April 2021
Biotech: Who will survive when the Covid-19 Hype Ends? Part II

For part I of this series please click here. Cities across Canada are gradually returning to business as usual, and we’re winning the fight against Covid-19 (don’t look south of the border). Thanks to all citizens still wearing hats to hide their botched home-haircuts, and our essential workers who literally put their lives on the…

7 July 2020